{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:05:34Z","timestamp":1776089134133,"version":"3.50.1"},"reference-count":10,"publisher":"American Association for Cancer Research (AACR)","issue":"3","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,5]]},"abstract":"<jats:sec>\n                    <jats:title>Summary:<\/jats:title>\n                    <jats:p>In this issue of Blood Cancer Discovery, Pomeroy and Palmer present a new mathematical model, incorporating both inter- and intra-patient heterogeneity, to accurately predict outcomes for first-line combination therapies in diffuse large B-cell lymphoma. Their quantitative framework opens a range of possibilities for optimizing trial design and lymphoma therapy with potential to expedite clinical development.<\/jats:p>\n                    <jats:p>See related article by Pomeroy and Palmer, p. 254<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-25-0071","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T09:32:56Z","timestamp":1744709576000},"page":"153-156","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond Trial and Error: A Mathematical Model Wrangles DLBCL Heterogeneity Toward Optimizing Combination Therapy"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4434-5070","authenticated-orcid":false,"given":"Jordan S.","family":"Goldstein","sequence":"first","affiliation":[{"name":"Division of Oncology, Stanford University, Stanford, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7624-7139","authenticated-orcid":false,"given":"Nick A.","family":"Phillips","sequence":"additional","affiliation":[{"name":"Division of Oncology, Stanford University, Stanford, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5153-5625","authenticated-orcid":false,"given":"Ash A.","family":"Alizadeh","sequence":"additional","affiliation":[{"name":"Division of Oncology, Stanford University, Stanford, California."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"key":"2026041309321748500_bib1","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N Engl J Med"},{"key":"2026041309321748500_bib2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"issue":"Suppl_17","key":"2026041309321748500_bib3","doi-asserted-by":"crossref","first-page":"LBA7003","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA7003","article-title":"Tucidinostat plus R-CHOP in previously untreated diffuse large B-cell lymphoma with double expression of MYC and BCL2: an interim analysis from the phase III DEB study","volume":"42","author":"Zhao","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026041309321748500_bib4","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1182\/blood-2017-11-764332","article-title":"Genetics of diffuse large B-cell lymphoma","volume":"131","author":"Pasqualucci","year":"2018","journal-title":"Blood"},{"issue":"Suppl 1","key":"2026041309321748500_bib5","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1182\/blood-2024-209735","article-title":"Anatomic genetic heterogeneity is uncovered by concurrent cell-free DNA and tissue profiling and predicts treatment resistance in diffuse large B-cell lymphoma","volume":"144","author":"Goldstein","year":"2024","journal-title":"Blood"},{"key":"2026041309321748500_bib6","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1158\/2643-3230.BCD-24-0230","article-title":"A model of intra-tumor and inter-patient heterogeneity explains clinical trials of curative combination therapy for lymphoma","volume":"6","author":"Pomeroy","year":"2025","journal-title":"Blood Cancer Discov"},{"key":"2026041309321748500_bib7","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1056\/NEJMoa2401532","article-title":"Combination targeted therapy in relapsed diffuse large B-cell lymphoma","volume":"390","author":"Melani","year":"2024","journal-title":"N Engl J Med"},{"key":"2026041309321748500_bib8","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.ccell.2023.09.004","article-title":"Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: the randomized GUIDANCE-01 trial","volume":"41","author":"Zhang","year":"2023","journal-title":"Cancer Cell"},{"key":"2026041309321748500_bib9","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41408-024-01090-y","article-title":"Patient-specific computational models predict prognosis in B cell lymphoma by quantifying pro-proliferative and anti-apoptotic signatures from genetic sequencing data","volume":"14","author":"Norris","year":"2024","journal-title":"Blood Cancer J"},{"key":"2026041309321748500_bib10","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.3390\/biomedicines9111655","article-title":"Patient-specific modeling of diffuse large B-cell lymphoma","volume":"9","author":"Thobe","year":"2021","journal-title":"Biomedicines"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-25-0071\/3582094\/bcd-25-0071.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/6\/3\/153\/3601199\/bcd-25-0071.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/6\/3\/153\/3601199\/bcd-25-0071.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T13:32:26Z","timestamp":1776087146000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/6\/3\/153\/762108\/Beyond-Trial-and-Error-A-Mathematical-Model"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,15]]},"references-count":10,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,4,15]]},"published-print":{"date-parts":[[2025,5,5]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-25-0071","relation":{},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,15]]}}}